Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy

Kidney International

Volumn 66, Issue 3, 2004, Pages 1180-1186

  Hovind, Peter ^a   Tarnow, Lise ^b   Rossing, Peter ^b   Carstensen, Bendix ^b   Parving, Hans Henrik ^b  

^a STENO DIABETES CENTER   (Denmark)

^b NONE

Author keywords

Antihypertensive treatment; Diabetic nephropathy; End stage renal disease; Mortality; Nephrotic range albuminuria; Remission; Type 1 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EDETATE CHROMIUM CR 51; INSULIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD ASSESSMENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTIC RANGE ALBUMINURIA; ONSET AGE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEINURIA; REGRESSION ANALYSIS; REMISSION; RISK ASSESSMENT; SURVIVAL;

EID: 4344623453     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00870.x     Document Type: Article

References (32)

1. PARVING H-H, OSTERBY R, RITZ E: Diabetic nephropathy (chapter 39). in The Kidney, 6th ed, edited by Brenner BM, Philadelphia, WB Saunders, 2000, pp 1731-1773
2. MOGENSEN CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36:383-388, 1976
3. PARVING H-H, SMIDT UM, FRIISBERG B, et al: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20:457-461, 1981
4. VIBERTI GC, BILOUS RW, MACKINTOSH D, et al: Monitoring glomerular function in diabetic nephropathy. Am J Med 74:256-264, 1983
5. BORCH-JOHNSEN K, KREINER S: Proteinuria: Value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 294:1651-1654, 1987
6. ROSSING P: Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabetic Med 15:900-919, 1998
7. WATKINS PJ, BLAINEY JD, BREWER DB, et al: The natural history of diabetic renal disease. A follow-up study of series of renal biopsies. Q J Med 41:437-456, 1972
8. AUSTIN SM, LIEBERMAN JS, NEWTON LD, et al: Slope of serial glomerular filtration rate and the progression of diabetic glomerular disease. J Am Soc Nephrol 3:1358-1370, 1993
9. KUSSMAN MJ, GOLDSTEIN HH, GLEASON RE: The clinical course of diabetic nephropathy. JAMA 236:1861-1863, 1976
10. HOVIND P, ROSSING P, TARNOW L, et al: Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24:1972-1977, 2001
11. PARVING H-H, ANDERSEN AR, SMIDT UM, et al: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179, 1983
12. BRÖCHNER-MORTENSEN J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30:271-274, 1972
13. AMERICAN DIABETES ASSOCIATION: Treatment of hypertension in diabetes. Diabetes Care 16:1394-1401, 1993
14. HOVIND P, ROSSING P, TARNOW L, et al: Progression of diabetic nephropathy. Kidney Int 59:702-709, 2001
15. WILMER WA, HEBERT LA, LEWIS EJ, et al: Remission of nephrotic syndrome in type 1 diabetes: Long-term follow-up of patients in the captopril study. Am J Kidney Dis 34:308-314, 1999
16. EKNOYAN G, HOSTETTER T, BAKRIS GL, et al: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42:617-622, 2003
17. BORCH-JOHNSEN K, ANDERSEN PK, DECKERT T: The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28:590-596, 1985
18. DE ZEEUW D, REMUZZI G, PARVING H-H, et al: Proteinuria, a therapy target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 (in press)
19. ROSSING P, HOUGAARD P, BORCH-JOHNSEN K, et al: Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br Med J 313:779-784, 1996
20. ABOUNA GM, KREMER GD, DADDAH SK, et al: Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet 2:1274-1276, 1983
21. FIORETTO P, STEFFES MW, SUTHERLAND DER, et al: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998
22. ANDERSEN AR, CHRISTIANSEN JS, ANDERSEN JK, et al: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 25:496-501, 1983
23. KROLEWSKI AS, WARRAM JH, CHRISTLIEB AR, et al: The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785-794, 1985
24. KNOWLES HC, GUEST GM, LAMPE J, et al: The course of juvenile diabetes treated with unmeasured diet. Diabetes 239-273, 1965
25. PARVING H-H, JACOBSEN P, ROSSING K, et al: Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49:1778-1782, 1996
26. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157:2413-2446, 1997
27. NUESCH R, SCHROEDER K, DIETERLE T, et al: Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: A prospective case-control study. Br Med J 323:142-146, 2001
28. LEWIS E, HUNSICKER L, BAIN R, et al: The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
29. BJÖRCK S, MULEC H, JOHNSEN SAA, et al: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339-343, 1992
30. EXNER DV, DRIES DL, DOMANSKI MJ, et al: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344:1351-1357, 2001
31. EVANS WE, MCLEOD HL: Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med 348:538-549, 2003
32. KALOW W, TANG BK, ENDRENYI L: Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8:283-289, 1998